TrialCNS drugs2026

Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Ignacio Bejarano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.